Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.9K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.9K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

4.2K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

74
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

1.2K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.2K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

5.1K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
5.1K
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

2.0K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small RNAs, big potential: Engineering microRNA-based synthetic gene circuits.

Current opinion in chemical biology·2026
Same author

Repurposing nuclear receptors for ligand-responsive liquid condensate formation and gene regulation.

Nature communications·2026
Same author

Self-assembling protein cages: from coiled-coil module to machine learning-driven <i>de novo</i> design of next-generation biomaterials.

Materials advances·2025
Same author

RNA <i>trans</i>-splicing to rescue β-catenin: A novel approach for treating CTNNB1-Haploinsufficiency disorder.

Molecular therapy. Nucleic acids·2025
Same author

Engineering chimeric PCSK9 for a vaccine against atherosclerosis.

Molecular therapy. Methods & clinical development·2025
Same author

Genotypic, functional, and phenotypic characterization in CTNNB1 neurodevelopmental syndrome.

HGG advances·2025
Same journal

Fast Generation of F(Ab')<sub>2</sub> Fragments From Human IgG Using Fc-Fused IgG-Degrading Enzyme.

European journal of immunology·2026
Same journal

Generation of Regulatory T Cells Against Islet Neoantigen.

European journal of immunology·2026
Same journal

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

European journal of immunology·2026
Same journal

Special Issue: yEFIS 3rd Symposium.

European journal of immunology·2026
Same journal

CRISPR/Cas9-Mediated Gene Knockout Reveals a Nonredundant Role for p16<sup>INK4A</sup> in Controlling TCR-Dependent and Independent CD8 T Cell Expansion.

European journal of immunology·2026
Same journal

Induction of Humoral and Cellular Immunity After SARS-CoV-2 JN.1 Vaccination in Individuals With and Without Prior Infection.

European journal of immunology·2026
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

13.1K

Postulates for validating TLR4 agonists.

Mateja Manček-Keber1, Roman Jerala

  • 1Department of Biotechnology, National Institute of Chemistry, Ljubljana, Slovenia; EN-FIST Centre of Excellence, Ljubljana, Slovenia.

European Journal of Immunology
|December 6, 2014
PubMed
Summary
This summary is machine-generated.

Toll-like receptors (TLRs) are key to innate immunity. We propose three postulates to differentiate direct TLR4 agonists from indirect activators, aiding research into sterile inflammation and viral infections.

Keywords:
Ligand recognitionMolecular mechanismTLR4 agonists

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.1K
High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.8K

Related Experiment Videos

Last Updated: Apr 19, 2026

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

13.1K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.1K
High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.8K

Area of Science:

  • Immunology
  • Molecular Biology
  • Biochemistry

Background:

  • Toll-like receptors (TLRs) are crucial pattern recognition receptors in the innate immune system.
  • TLR4, with its co-receptor myeloid differentiation-2 (MD-2), typically recognizes bacterial lipopolysaccharide (LPS) from Gram-negative bacteria.
  • However, TLR4 is implicated in diverse pathophysiological states, including sterile inflammation and viral infections, due to numerous reported endogenous agonists.

Purpose of the Study:

  • To address the mechanistic challenge of a single receptor being activated by a wide array of structurally diverse molecules.
  • To propose a framework for distinguishing direct agonists from indirect activators of TLR4.
  • To offer postulates applicable to other pattern recognition receptors.

Main Methods:

  • Postulate 1: Direct agonists must require the TLR4/MD-2 receptor complex for activation.
  • Postulate 2: Synthetic or in situ generated agonists are necessary to prevent contamination artifacts.
  • Postulate 3: Identification of specific molecular interactions between the agonist and the TLR4-MD-2 complex is required.

Main Results:

  • The study proposes three distinct postulates to rigorously identify direct TLR4 agonists.
  • These postulates aim to resolve the complexity arising from numerous reported endogenous TLR4 activators.
  • The framework is designed to ensure mechanistic clarity in TLR4 signaling.

Conclusions:

  • A clear distinction between direct and indirect TLR4 agonists is essential for understanding its diverse roles.
  • The proposed postulates provide a robust methodology for identifying true TLR4 agonists.
  • This framework can be generalized to investigate other pattern recognition receptors in innate immunity.